(Q54530558)

31 May 2018

title

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. (English)

1 reference

31 May 2018

main subject

crizotinib

1 reference

ChEBI release 2020-05-28

2

William Pao

1 reference

31 May 2018

1

Christine M Lovly

1 reference

31 May 2018

language of work or name

English

0 references

publication date

1 February 2012

1 reference

31 May 2018

Science Translational Medicine

published in

1 reference

31 May 2018

volume

4

1 reference

31 May 2018

page(s)

120ps2

1 reference

31 May 2018

issue

120

1 reference

31 May 2018

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Inflammatory myofibroblastic tumours: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003728

10.1126/SCITRANSLMED.3003728

21 January 2018

Identifiers

DOI

1 reference

31 May 2018

PubMed ID

22323827

1 reference

31 May 2018